| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 2973187 | The Journal of Heart and Lung Transplantation | 2007 | 9 Pages |
Abstract
Everolimus significantly reduced acute rejection and limited the progression of allograft vasculopathy at 24 months compared with azathioprine. Although graft and patient survival was comparable at 24 months, everolimus therapy may improve longer-term outcomes after heart transplantation.
Related Topics
Health Sciences
Medicine and Dentistry
Cardiology and Cardiovascular Medicine
Authors
Mario MD, Murat MD, Raymond MD, Pascale MD, Axel MD, James MD, Guenther MD, Robert MD, Jayan MD, Luis Alonso MD, Dale MD, Kamal PhD, Nathalie MD, Randall C. MD, Howard J. MD, RAD B253 Study Group RAD B253 Study Group,